Stock Events

Stock Events

Telix Pharmaceuticals 

$10.80
133
+$0.08+0.75%Monday 15:01

Statistics

Day High
10.8
Day Low
10.8
52W High
13
52W Low
5.91
Volume
100
Avg. Volume
2,077
Mkt Cap
3.67B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Aug 19Expected
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.02
0.06
0.13
0.21
Expected EPS
0.06272663485826552
Actual EPS
0.15071568902610163

Financials

-0.89%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
803.79MRevenue
-7.13MNet Income

Analyst Ratings

$21.33Average Price Target
The highest estimate is ⁦22.00⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TLPPF. It's not an investment recommendation.
CSL
27
CSL.AU
NVIDIA
17
NVDA
WiseTech Global Limited
17
WTC.AU
Microsoft
16
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alternative Access First Priority CLO Bond
AAA
Mkt Cap0
Advanced Accelerator Applications, a Novartis company, competes in the radiopharmaceuticals market for diagnostic and therapeutic applications, similar to Telix's focus area.
ClearPoint Neuro
CLPT
Mkt Cap332.34M
ClearPoint Neuro, Inc. specializes in precision delivery of therapeutics to the brain, competing in the neuro-oncology segment where Telix also operates.
Novartis
NVS
Mkt Cap268B
Novartis AG, through its acquisitions and internal development, competes across a broad range of therapeutic areas including those targeted by Telix's radiopharmaceuticals.
Bausch Health Companies
BHC
Mkt Cap2.17B
Bausch Health Companies Inc. has a diverse portfolio that includes products competing in the oncology and radiopharmaceutical sectors.
Protagonist Therapeutics
PTGX
Mkt Cap9.06B
Protagonist Therapeutics, Inc. is involved in the development of peptide-based therapeutics, competing in the innovative treatment space including cancer, where Telix is also active.
Dr. Reddy`s Laboratories
RDY
Mkt Cap10.2B
Dr. Reddy’s Laboratories Ltd. manufactures and markets a wide range of pharmaceuticals globally, including generic versions of drugs that compete with Telix's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol-Myers Squibb Company operates in the oncology space with a broad portfolio of drugs that compete with Telix Pharmaceuticals in the cancer treatment market.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly and Company has a strong presence in oncology and radiopharmaceuticals, directly competing with Telix in several therapeutic areas.
Pfizer
PFE
Mkt Cap158.45B
Pfizer Inc. is a global pharmaceutical giant with a diverse portfolio, including oncology and radiopharmaceuticals, making it a competitor in multiple areas relevant to Telix.

About

Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
Show More
CEO
Christian Behrenbruch
Employees
1184
Country
Australia
ISIN
AU000000TLX2
WKN
000A2H7JK

Listings

MX
MX
TLX1N.MX
AU
AU
TLX.AU
F
DE
T3X0.F
OTC Link
US
TLPPF

0 Comments

Share your thoughts

FAQs

What is Telix Pharmaceuticals stock price today?▼
The current price of TLPPF is $10.80 USD — it has increased by +0.75% in the past 24 hours. Watch Telix Pharmaceuticals stock price performance more closely on the chart.
What is Telix Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Telix Pharmaceuticals stocks are traded under the ticker TLPPF.
Is Telix Pharmaceuticals stock price growing?▼
TLPPF stock has fallen by -12.9% compared to the previous week, the month change is a -1.73% fall, over the last year Telix Pharmaceuticals has showed a +13.68% increase.
What is Telix Pharmaceuticals market cap?▼
Today Telix Pharmaceuticals has the market capitalization of 3.67B
When is the next Telix Pharmaceuticals earnings date?▼
Telix Pharmaceuticals is going to release the next earnings report on February 19, 2027.
What were Telix Pharmaceuticals earnings last quarter?▼
TLPPF earnings for the last quarter are 0.11 USD per share, whereas the estimation was 0.04 USD resulting in a +140.27% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Telix Pharmaceuticals revenue for the last year?▼
Telix Pharmaceuticals revenue for the last year amounts to 803.79M USD.
What is Telix Pharmaceuticals net income for the last year?▼
TLPPF net income for the last year is -7.13M USD.
How many employees does Telix Pharmaceuticals have?▼
As of October 6, 2026, the company has 1,184 employees.
In which sector is Telix Pharmaceuticals located?▼
Telix Pharmaceuticals operates in the Health & Wellness sector.
When did Telix Pharmaceuticals complete a stock split?▼
Telix Pharmaceuticals has not had any recent stock splits.
Where is Telix Pharmaceuticals headquartered?▼
Telix Pharmaceuticals is headquartered in North Melbourne, Australia.